178 related articles for article (PubMed ID: 18316572)
1. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells.
Black PC; Brown GA; Inamoto T; Shrader M; Arora A; Siefker-Radtke AO; Adam L; Theodorescu D; Wu X; Munsell MF; Bar-Eli M; McConkey DJ; Dinney CP
Clin Cancer Res; 2008 Mar; 14(5):1478-86. PubMed ID: 18316572
[TBL] [Abstract][Full Text] [Related]
2. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines.
Wallerand H; Cai Y; Wainberg ZA; Garraway I; Lascombe I; Nicolle G; Thiery JP; Bittard H; Radvanyi F; Reiter RR
Urol Oncol; 2010; 28(2):180-8. PubMed ID: 19070520
[TBL] [Abstract][Full Text] [Related]
3. Receptor heterodimerization: a new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer.
Black PC; Brown GA; Dinney CP; Kassouf W; Inamoto T; Arora A; Gallagher D; Munsell MF; Bar-Eli M; McConkey DJ; Adam L
J Urol; 2011 Feb; 185(2):693-700. PubMed ID: 21168861
[TBL] [Abstract][Full Text] [Related]
4. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.
Yauch RL; Januario T; Eberhard DA; Cavet G; Zhu W; Fu L; Pham TQ; Soriano R; Stinson J; Seshagiri S; Modrusan Z; Lin CY; O'Neill V; Amler LC
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8686-98. PubMed ID: 16361555
[TBL] [Abstract][Full Text] [Related]
5. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents.
Jimeno A; Rubio-Viqueira B; Amador ML; Oppenheimer D; Bouraoud N; Kulesza P; Sebastiani V; Maitra A; Hidalgo M
Cancer Res; 2005 Apr; 65(8):3003-10. PubMed ID: 15833824
[TBL] [Abstract][Full Text] [Related]
7. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors.
Baumgart E; Cohen MS; Silva Neto B; Jacobs MA; Wotkowicz C; Rieger-Christ KM; Biolo A; Zeheb R; Loda M; Libertino JA; Summerhayes IC
Clin Cancer Res; 2007 Mar; 13(6):1685-94. PubMed ID: 17363521
[TBL] [Abstract][Full Text] [Related]
8. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance.
Krumbach R; Schüler J; Hofmann M; Giesemann T; Fiebig HH; Beckers T
Eur J Cancer; 2011 May; 47(8):1231-43. PubMed ID: 21273060
[TBL] [Abstract][Full Text] [Related]
9. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
Damiano V; Caputo R; Bianco R; D'Armiento FP; Leonardi A; De Placido S; Bianco AR; Agrawal S; Ciardiello F; Tortora G
Clin Cancer Res; 2006 Jan; 12(2):577-83. PubMed ID: 16428503
[TBL] [Abstract][Full Text] [Related]
10. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
Patel D; Bassi R; Hooper A; Prewett M; Hicklin DJ; Kang X
Int J Oncol; 2009 Jan; 34(1):25-32. PubMed ID: 19082474
[TBL] [Abstract][Full Text] [Related]
11. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
[TBL] [Abstract][Full Text] [Related]
12. Mammary-derived growth inhibitor alters traffic of EGFR and induces a novel form of cetuximab resistance.
Nevo J; Mattila E; Pellinen T; Yamamoto DL; Sara H; Iljin K; Kallioniemi O; Bono P; Heikkilä P; Joensuu H; Wärri A; Ivaska J
Clin Cancer Res; 2009 Nov; 15(21):6570-81. PubMed ID: 19825952
[TBL] [Abstract][Full Text] [Related]
13. ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer.
Geißler AL; Geißler M; Kottmann D; Lutz L; Fichter CD; Fritsch R; Weddeling B; Makowiec F; Werner M; Lassmann S
Oncotarget; 2017 Mar; 8(10):17164-17190. PubMed ID: 28199979
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor inducing bladder cancer progression by promoting an epithelial-mesenchymal transition.
Jitao W; Jinchen H; Qingzuo L; Li C; Lei S; Jianming W; Zhenli G
Andrologia; 2014 Dec; 46(10):1128-33. PubMed ID: 24329492
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth.
Gómez-Román JJ; Saenz P; Molina M; Cuevas González J; Escuredo K; Santa Cruz S; Junquera C; Simón L; Martínez A; Gutiérrez Baños JL; López-Brea M; Esparza C; Val-Bernal JF
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):459-65. PubMed ID: 15701828
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder.
Wang X; Zhang S; MacLennan GT; Eble JN; Lopez-Beltran A; Yang XJ; Pan CX; Zhou H; Montironi R; Cheng L
Clin Cancer Res; 2007 Feb; 13(3):953-7. PubMed ID: 17289890
[TBL] [Abstract][Full Text] [Related]
17. Modulation of gene expression and cell-cycle signaling pathways by the EGFR inhibitor gefitinib (Iressa) in rat urinary bladder cancer.
Lu Y; Liu P; Van den Bergh F; Zellmer V; James M; Wen W; Grubbs CJ; Lubet RA; You M
Cancer Prev Res (Phila); 2012 Feb; 5(2):248-59. PubMed ID: 21982874
[TBL] [Abstract][Full Text] [Related]
18. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
Khambata-Ford S; Garrett CR; Meropol NJ; Basik M; Harbison CT; Wu S; Wong TW; Huang X; Takimoto CH; Godwin AK; Tan BR; Krishnamurthi SS; Burris HA; Poplin EA; Hidalgo M; Baselga J; Clark EA; Mauro DJ
J Clin Oncol; 2007 Aug; 25(22):3230-7. PubMed ID: 17664471
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor--its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinomas.
Mrhalova M; Plzak J; Betka J; Kodet R
Neoplasma; 2005; 52(4):338-43. PubMed ID: 16059652
[TBL] [Abstract][Full Text] [Related]
20. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice.
Perrotte P; Matsumoto T; Inoue K; Kuniyasu H; Eve BY; Hicklin DJ; Radinsky R; Dinney CP
Clin Cancer Res; 1999 Feb; 5(2):257-65. PubMed ID: 10037173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
